Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Significance of ERIC study in identifying p53 mutants in CLL

Kostas Stamatopoulos, MD, PhD, of the Center for Research and Technology Hellas, Thermi, Greece, explores the result of an ERIC multi-center study evaluating the use of next-generation sequencing to identify micro-clones with TP53 mutations in chronic lymphocytic leukemia (CLL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).